Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2022-08-04 Director's Dealing
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Allegato 3F - Luglio 2022
Director's Dealing Classification · 1% confidence The document is a formal disclosure titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE" (Model Disclosure for Transactions in the Issuer's Securities). It details transactions (purchases 'A' and sales 'V') in the issuer's shares (Pharmanutra S.p.A.) conducted by a party named INTERMONTE SPA during July 2022. This type of filing specifically reports personal share transactions by executives, directors, or related parties (insiders) or, as in this case, transactions by entities closely related to the issuer's operations/management, which falls under the scope of insider dealing or director's dealing disclosures, even if the reporting party is an intermediary or related entity. Reviewing the definitions: - 10-K/IR: Not an annual or interim comprehensive report. - ER/MDA: Not an earnings release or management discussion. - CT/IP: Not a transcript or presentation. - DVA: Not voting results. - The content explicitly details transactions in the issuer's securities by a specific party, matching the description for Director's Dealing (DIRS) or similar insider transaction reporting, which is often grouped under DIRS in many regulatory frameworks, especially when reporting transactions by related parties. - The closest specific match is 'Director's Dealing (Code: DIRS)' which covers 'Report of personal share transactions by company directors and executives (insider trades)'. Although the reporting party is 'INTERMONTE SPA', the structure and content (transactions in issuer's securities) strongly align with insider transaction reporting requirements. - It is not a general regulatory filing (RNS) because it fits the specific category DIRS. - It is not a Transaction in Own Shares (POS) because POS refers to the company buying back its own shares, whereas this details transactions by a third party (INTERMONTE SPA) in the company's shares.
2022-08-04 Italian
PHARMANUTRA - First Closing Acquisition Akern S.r.l.
M&A Activity Classification · 1% confidence The document is a formal communication titled "PHARMANUTRA S.P.A.: FIRST ACQUISITION CLOSING OF AKERN S.R.L. FINALISED". It details the completion of the first closing stage of an acquisition, including financial figures (€ 10,783,200 invested), management structure post-acquisition, and future closing plans. This type of announcement, concerning significant corporate transactions like M&A, is typically classified under Merger/Takeover Activity (TAR). Although it is a detailed announcement, it is not the full regulatory filing (like a 10-K) nor is it a general regulatory filing (RNS). It specifically concerns a transaction proposal/completion, fitting the definition of M&A Activity (TAR). The document length (6725 chars) is substantial enough to be the primary announcement rather than just a placeholder for a report.
2022-07-26 English
PHARMANUTRA - Primo Closing Operazione di acquisizione Akern S.r.l.
M&A Activity Classification · 1% confidence The document is an official communication from PHARMANUTRA S.P.A. dated July 26, 2022, regarding the completion of the first closing of the acquisition of Akern S.r.l. The header indicates it is 'Informazione Regolamentata' (Regulated Information) and the subject is 'Primo Closing Operazione di acquisizione Akern S.r.l.' (First Closing of the acquisition of Akern S.r.l.). This type of announcement, detailing a significant corporate transaction (M&A activity), is typically classified under Merger & Acquisition Activity (TAR) or, if it's a general regulatory disclosure not fitting other specific categories, potentially RNS. Since the core content is the completion of a takeover/acquisition step, TAR (Transaction/Acquisition Report) is the most specific fit, although it is a notification of the event rather than the full merger agreement. Given the options, M&A Activity (TAR) is the best fit for an acquisition closing announcement. It is not a standard financial report (10-K, IR, ER) or a proxy/dividend notice.
2022-07-26 Italian
Allegato 3F - Giugno 2022
Transaction in Own Shares Classification · 1% confidence The document is a formal disclosure titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE" (Model Disclosure for Transactions in the Issuer's Securities) from PHARMANUTRA S.P.A., dated July 6, 2022, referencing transactions in June 2022. It details specific transactions (purchases, 'A' for Acquisto) made by a party (INTERMONTE SPA) involving the issuer's shares. This structure, focusing on transactions in the issuer's own shares, directly corresponds to the definition of 'Transaction in Own Shares' (POS). Although it reports on transactions, the context is specifically about the company's own shares being bought/sold, which is the core of POS, rather than general insider trading (DIRS). The document is a structured regulatory filing, not a general announcement (RPA/RNS), as it contains the detailed transaction data itself.
2022-07-06 Italian
PHARMANUTRA: Golden Power notification for 100% Akern S.r.l. acquisition
Regulatory Filings Classification · 1% confidence The document is an official regulatory notification from PHARMANUTRA, identified by the header 'Informazione Regolamentata n. 20106-46-2022' and the 'Oggetto' (Subject) concerning a 'Golden Power notification for 100% Akern S.r.l. acquisition'. This filing details a significant corporate transaction (M&A activity) and the required regulatory clearance process (Golden Power notification in Italy). While it relates to an acquisition (TAR), the core content is a mandatory regulatory disclosure about the process and conditions of the deal, rather than the M&A proposal itself or a general earnings announcement. Since it is a specific regulatory filing that doesn't fit perfectly into the M&A (TAR) or Capital (CAP) categories, and it is a formal announcement of a regulatory step, the most appropriate general category for specific, non-standard regulatory disclosures that are not earnings or annual reports is Regulatory Filings (RNS). However, given the subject is explicitly about a transaction/acquisition, and the document is short and announces the filing of a notification related to the acquisition, it strongly relates to M&A Activity (TAR). Since the definition for TAR is 'Announcements and documents related to merger proposals or takeover bids,' and this is a key regulatory step *in connection with* an acquisition, TAR is a strong candidate. Alternatively, because it is a formal regulatory filing ('Informazione Regolamentata') that doesn't fit the specific financial report types, RNS is the fallback. Given the explicit mention of 'acquisition' and the nature of the filing being a mandatory step in that process, TAR is more specific than RNS. However, the document is essentially an announcement that a notification was filed, and the main text is brief, stating 'Vedi allegato' (See attachment) and then detailing the regulatory filing. This structure often points towards an RPA or RNS. Since it is a specific regulatory filing about a transaction, and not the transaction proposal itself, RNS (General regulatory announcements and fallback category) is the safest classification for a specific regulatory step notification that isn't a standard financial report.
2022-06-17 English
PHARMANUTRA: Deposito notifica Golden Power per acquisizione 100% di Akern S.r.l.
Legal Proceedings Report Classification · 1% confidence The document is an official communication from PHARMANUTRA, identified by the header "Informazione Regolamentata n. 20106-45-2022" and the subject line: "PHARMANUTRA: Deposito notifica Golden Power per acquisizione 100% di Akern S.r.l.". This filing concerns the mandatory notification (Golden Power notification) to the Presidency of the Council of Ministers regarding the acquisition of a controlling stake in another company (Akern S.r.l.). This type of announcement, detailing a significant corporate transaction or regulatory compliance step related to M&A activity, fits best under the category of M&A Activity (TAR) or potentially a general Regulatory Filing (RNS). Since the core subject is the acquisition/takeover process and the required regulatory filing associated with it, TAR (Merger/Takeover Activity) is the most specific fit, even though it is a notification *about* the M&A process rather than the final deal document. Given the specific nature of the 'Golden Power' notification related to an acquisition, TAR is chosen over the general RNS.
2022-06-17 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.